To propel novel immunotherapy programs, clinical-stage biotech startup Abcuro concluded an oversubscribed Series B financing round, securing $155 million. The funding was co-led by investment firms Redmile Group and Bain Capital Life Sciences, drawing participation from new and existing investors.
The infusion of funds will accelerate Abcuro’s pivotal development initiatives, which aim at addressing critical therapeutic gaps in diseases with limited or no viable treatment options.
With a solid commitment to serving patients, Abcuro is now well-positioned to advance its clinical trials, highlighted by the notable progress of its registrational trial for inclusion body myositis (IBM).
Targeted Immunotherapy: ABC008’s Promising Approach
Abcuro’s central focus is its groundbreaking lead candidate, ABC008, a pioneering monoclonal antibody that precisely targets the killer cell lectin-like receptor G1 (KLRG1). This unique therapeutic modality can selectively eliminate highly cytotoxic T cells while sparing vital immune components such as naïve, regulatory, and central memory T cells.
The clinical data observed thus far has ignited excitement among researchers and clinicians alike.
The success of the ongoing Phase 2/3 registrational clinical trial for inclusion body myositis (IBM) underscores the potential of ABC008 in addressing this challenging autoimmune muscle disease, for which treatment options are scarce.
Beyond Boundaries: Diversifying Treatment Applications
The utility of ABC008 extends beyond its application in IBM, as Abcuro is strategically advancing its investigative efforts.
A Phase 1/2 clinical trial is underway to target T cell large granular lymphocytic leukemia (T-LGLL). In contrast, plans for a Phase 1/2 trial for T and NK cell lymphomas are set to be initiated.
At the heart of Abcuro’s innovation lies the pivotal role of killer cell lectin-like receptor G1 (KLRG1). This immune checkpoint receptor is strategically expressed on specific T cell subsets, making it an ideal target for immune modulation in autoimmune diseases and cancer.
By honing in on cytotoxic T and NK cells, Abcuro’s approach holds the promise of precision therapy while maintaining immune system equilibrium.
A Vision for the Future: Abcuro’s Mission and Leadership
CEO Alex Martin and Chief Medical Officer H. Jeffrey Wilkins, M.D lead Abcuro. Their collective vision is centered on advancing innovative immunotherapies that harness the potential of cytotoxic T and NK cells, offering renewed hope to patients grappling with autoimmune diseases and cancer.
The resounding success of Abcuro’s Series B financing round is a testament to the strong backing of a diverse group of investors.
Notable participants include RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Ventures, Pontifax, funds managed by Tekla Capital Management, funds and accounts managed by BlackRock, Mass General Brigham Ventures, Eurofarma, and Soleus Capital.
With an impressive infusion of funds and a solid foundation of promising clinical data, Abcuro is primed to usher in a new era of targeted immunotherapies.
As the company’s innovative ABC008 continues to demonstrate its potential in diverse disease areas, the global medical community eagerly anticipates the transformative impact Abcuro’s breakthroughs will have on patients’ lives.
Follow USTechTimes on Facebook, Twitter and Linkedin for in-depth news of market trends, funding updates, and regulatory changes affecting startups in USA.
We Recomend:
- Odyssey Therapeutics bags $168 million to expand its range of cancer drugs
- AltPep Raises $52.9M to transform amyloid disease treatments and detection
- Nexo Therapeutics Raises $60M Series A Funding for Innovative Cancer Therapies
- Odyssey Therapeutics bags $168 million to expand its range of cancer drugs
- Renibus Therapeutics secures $47M funding to advance promising drug for postoperative complications following cardiothoracic surgery
